The authorised remdesivir for COVID-19 on the basis of 1 outcome from the NIAID trial. This outcome was switched, the trial is unpublished, and we have no good evidence remdesivir reduces mortality. Our piece for
🇫🇮:ssa 8 sairaalassa #SOLIDARITYtrial:issa tutkitaan #remdesiviiri:ä. Päätemuuttujat: kuolema, tehohoidon riski & haitat. Näin piti olla 🇺🇸:ssa trialissa. Sitten vaihdettiin päätemuuttuja, keskeytettiin tutkimus ja FDA antoi luvan käyttöön. Surkeaa!
2. If the drug can be patented, do everything to make it look it good. See Remdesivir, which has been recommended heavily by fiat science based on a press release based on one trial whose results, methods, data, and conclusions have yet to be published.
So it should go without saying that I agree with and colleagues here completely, and that I find this summary both scary and accurate.
The FDA has authorised remdesivir for use in COVID-19 patients: but there’s no good evidence it reduces mortality - CEBM
The has authorised remdesivir for use in COVID-19 #coronavirus patients: but there’s no good evidence it reduces mortality via & & &